Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate.
Total serum alkaline phosphatase (TSAP) determinations were done as part of the biochemical screening in comparative studies of lipid lowering agents in type lla hyperlipoproteinemic patients. TSAP determinations were made by using a modification of the Bessey-Lowry method and the Statland method. Increases in TSAP following colestipol treatment of 20% (P less than 0.05) and 32% (P less than 0.005) were seen by using the respective methods. Isoenzymatic determinations were done by employing the Statland method and all fractions were increased from baseline levels during colestipol therapy. Clofibrate was associated with 34% (P less than 0.005) and 28% (P less than 0.005) reductions in TSAP activity by using the respective methods; significant reductions in both "bone" and "other" isoenzymatic components occurred. Gamma-glutamyltransferase (gamma GT) results did not consistently reflect TSAP or "liver" isoenzyme results.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D002994:Clofibrate / Q000494:pharmacology*; D003084:Colestipol / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D008875:Middle Aged; D011073:Polyamines / Q000494:pharmacology*; D005723:gamma-Glutamyltransferase / Q000097:blood
D007527:Isoenzymes; D011073:Polyamines; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D002994:Clofibrate; D003084:Colestipol